Canton Strategic Holdings (CNTN) Cash & Equivalents (2020 - 2026)
Canton Strategic Holdings' (CNTN) quarterly Cash & Equivalents came in at $41.5 million in Q1 2026, up 3760.12% YoY from $1.1 million in Q1 2025, and up 143.84% on a QoQ basis from $17.0 million in Q4 2025.
Analysis
Canton Strategic Holdings (CNTN) Cash & Equivalents (2020 - 2026) Analysis & Trends
Canton Strategic Holdings (CNTN) has 7 years of Cash & Equivalents data on file, last reported at $41.5 million in Q1 2026.
- Quarterly Cash & Equivalents rose 3760.12% year-over-year to $41.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $41.5 million (up 3760.12% YoY) and the FY2025 annual result came in at $17.0 million, up 378.53% from the prior year.
- Cash & Equivalents advanced to $41.5 million in Q1 2026, from $17.0 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $41.5 million in Q1 2026 to a low of $1.1 million in Q1 2025.
- A 5-year average of $8.8 million and a median of $7.6 million in 2022 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2022 — Cash & Equivalents surged 149361.29% — and 2025, when it plunged 87.23%.
- Tracing CNTN's Cash & Equivalents over 5 years: stood at $6.5 million in 2022, then surged by 67.96% to $10.9 million in 2023, then slumped by 67.45% to $3.6 million in 2024, then jumped by 378.53% to $17.0 million in 2025, then jumped by 143.84% to $41.5 million in 2026.
- The last three Cash & Equivalents figures came in at $41.5 million (Q1 2026), $17.0 million (Q4 2025), and $7.6 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 3.58 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 1.72 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 815.44 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 5.10 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.71 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 811.99 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Canton Strategic Holdings | 493.37 Mn | 493.37 Mn | - | 37.24 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 37.24 Mn |
| Mar 31, 2026 | 41.53 Mn |
| Dec 31, 2025 | 12.01 Mn |
| Sep 30, 2025 | 7.61 Mn |
| Jun 30, 2025 | 2.24 Mn |
| Mar 31, 2025 | 1.08 Mn |
| Dec 31, 2024 | 3.56 Mn |
| Sep 30, 2024 | 4.77 Mn |
| Jun 30, 2024 | 7.90 Mn |
| Mar 31, 2024 | 8.43 Mn |
| Dec 31, 2023 | 10.94 Mn |
| Sep 30, 2023 | 2.69 Mn |
| Jun 30, 2023 | 3.90 Mn |
| Mar 31, 2023 | 3.57 Mn |
| Dec 31, 2022 | 6.51 Mn |
| Sep 30, 2022 | 7.60 Mn |
| Jun 30, 2022 | 9.48 Mn |
| Mar 31, 2022 | 11.12 Mn |
| Dec 31, 2021 | 4,356.00 |
| Sep 30, 2021 | 45,095.00 |